CD44v6和MMP2的同时表达预测了肺转移和骨髓瘤不良预后

Shoulei Liang1, Liang Li1, Zhiliang Guo1

  • 1Department of orthopedic, The Second Hospital of Tangshan, No.21, Jianshe North Road, Tangshan 063000, China.

概括

CD44变体v6 (CD44v6) 和矩阵金属蛋白酶2 (MMP2) 是骨髓瘤患者的关键预后指标. 它们的综合表达预测了无转移和整体存活率,指导治疗决策.